Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 ...
News Medical on MSN
Optimized costimulatory domains boost tumor killing in CAR NK cells
Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with ...
For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...
The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...
Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By ...
Indapta Therapeutics Presents Data Demonstrating Clinical Activity of its Allogeneic Natural Killer Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma Data from ongoing Phase 1/2 trial ...
Researchers expanded millions of cancer-targeting NK cells from a single donor, improving manufacturing for future therapies.
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...
SENTI-202, a CAR NK cell therapy, achieved complete remission in several relapsed/refractory AML patients, showing potential as an effective treatment option. The off-the-shelf nature of SENTI-202 ...
CD19 CAR-NK cell therapy with rituximab achieved durable complete responses in Waldenström Non-Hodgkin lymphoma, with up to 15 months of remission. The QUILT-106 study reported 100% disease control ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results